Written Question·Department of Health and Social Care·UIN 40092

Prostate Cancer: Hormone Treatments

Tabled: 20 March 2025

Answered: 25 March 2025

Named Day

Question

Helen Maguire

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential implications for his policies of the Institute of Cancer Research's report entitled Cost-utility analysis of adding abiraterone acetate plus prednisone/

Answer

Karin Smyth

Abiraterone has a United Kingdom marketing authorisation for the treatment of metastatic hormone-relapsed prostate cancer before chemotherapy is indicated, and for castration-resistant metastatic prostate cancer previously treated with a docetaxel-contain...

ⓘ

This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 40092) →